<DOC>
	<DOC>NCT00122837</DOC>
	<brief_summary>This is a clinical trial assessing duloxetine and comparator to placebo in patients who have generalized anxiety disorder.</brief_summary>
	<brief_title>A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Duloxetine Hydrochloride</mesh_term>
	<criteria>Male and female outpatients at least 18 years of age, presenting with generalized anxiety disorder (GAD). Any current and primary Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSMIV) Axis I diagnosis other than GAD. Patients diagnosed with major depressive disorder within the past 6 months or patients diagnosed with panic disorder, posttraumatic stress disorder, or an eating disorder within the past year or obsessivecompulsive disorder, bipolar affective disorder, psychosis factitious disorder, or somatoform disorders during their lifetime The presence of an Axis II disorder or history of antisocial behavior, which in the judgement of the investigator would interfere with compliance with study protocol Have previously completed or withdrawn from this study or any other study investigating duloxetine or have previously been treated with duloxetine History of alcohol or any psychoactive substance abuse or dependence (as defined in the DSMIVTR) within the past 6 months</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2007</verification_date>
</DOC>